Zimmer Biomet Holdings (ZBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Zimmer Biomet (ZBH) PT Raised to $117 at Truist Securities
October 31, 2024 12:37 PM EDTTruist Securities analyst Richard Newitter raised the price target on Zimmer Biomet (NYSE: ZBH) to $117.00 (from $112.00) while maintaining a Hold rating.
The analyst comments "ZBH's 3Q cc rev beat offset by ~90bps op margin miss; in-line EPS benefited from non-operating items and... More
Oppenheimer Reiterates Outperform Rating on Zimmer Biomet (ZBH)
October 30, 2024 4:28 PM EDTOppenheimer analyst Steven Lichtman reiterated an Outperform rating and $135.00 price target on Zimmer Biomet (NYSE: ZBH).
The analyst comments "3Q24 sales of $1.824B (+4.1% constant-currency) outpaced our/Street's $1.791B/$1.795B on less ERP headwind than expected and better than expected underlying performance, particularly in SET. Knees... More
